Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Entacapone/folic acid compound medicine composition and application thereof

A technology of entacapone and composition, applied in the field of pharmacy, to achieve the effects of increasing curative effect, preventing and reducing stroke, and overcoming the low efficacy of drugs

Inactive Publication Date: 2013-06-05
SUZHOU FAMO BIOLOGICAL TECH
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Entocapone is 100-200 mg each time, and the frequency of taking the compound levodopa is the same as that of the compound levodopa. Levodopa taken together, single use is invalid

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Entacapone/folic acid compound medicine composition and application thereof
  • Entacapone/folic acid compound medicine composition and application thereof
  • Entacapone/folic acid compound medicine composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Embodiment 1. Preparation of tablet

[0034] prescription:

[0035]

[0036] Preparation Process:

[0037] (1) Take the prescribed amount of entacapone and folic acid and pass through a 100-mesh sieve and mix them uniformly by the method of equal increments for subsequent use;

[0038] (2) Other auxiliary materials are passed through a 100-mesh sieve and dried at 75°C for 2 hours;

[0039] (3) Mix the starch, microcrystalline cellulose, and CMS.Na according to the prescription amount, and then mix them evenly with the mixed raw material drug in equal increments;

[0040] (4) Add an appropriate amount of binder to prepare soft materials, granulate with a 24-mesh sieve, granulate with a 20-mesh sieve, and dry at 40-75°C.

[0041] (5) Add an appropriate amount of magnesium stearate to the dry granules and mix evenly. After the content is determined, compress into tablets and pack.

[0042] 3 times a day, 1 tablet each time.

Embodiment 2

[0043] Embodiment 2. The preparation of capsule

[0044] prescription:

[0045]

[0046]

[0047] Preparation Process:

[0048] According to the prescription ratio, take lactose, microcrystalline cellulose, starch, and carboxymethyl starch sodium and dry them at about 100°C for about 2 hours, pass through a 100-mesh sieve; pass the raw material through a 100-mesh sieve, and increase the amount of the above-mentioned excipients in equal increments Mix well and fill the capsules.

[0049] 3 times a day, 1 capsule each time.

Embodiment 3

[0050] Example 3. Preparation of Sustained Release Tablets

[0051] prescription:

[0052]

[0053] Preparation Process:

[0054] According to the proportion of the prescription, the raw material is mixed with hypromellose, citric acid is dissolved in ethanol as a wetting agent to make a soft material, granulated, dried, sized, mixed with magnesium stearate, pressed Slice and serve.

[0055] 1 time every other day, 1-2 tablets each time.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an entacapone / folic acid compound medicine composition and application thereof and belongs to the technical field of pharmacy. The medicine composition contains officinal dose of entacapone, officinal dose of folic acid compound and a carrier acceptable in the pharmacy. The dose of the entacapone is 100-300mg, and the dose of the folic acid compound is 0.2-1.6mg. The entacapone / folic acid compound medicine composition has the advantages of strengthening curative effect on treatment of Parkinson's disease through multiple-target-point synergistic effect and improving the life quality of patients. The medicine composition still can effectively prevent and reduce the risk that Parkinson's disease patients are subjected to brain stroke through high homocysteine (Hcy) target points. In addition, the entacapone / folic acid compound medicine composition can be conveniently taken by the patients.

Description

technical field [0001] The invention relates to a pharmaceutical composition of entacapone / folate compound and its application, belonging to the technical field of pharmacy. Background technique [0002] Parkinson's disease (PD) is a chronic progressive disease of extrapyramidal dysfunction in the central nervous system. The main pathological manifestations of PD are the degeneration of dopamine (DA) neurons in the substantia nigra, and the decrease of the content of central neurotransmitter DA, and the degree of depletion of DA is consistent with the severity of PD; at the same time, it can also be accompanied by acetylcholine (Ach), 5- Abnormality and imbalance of various neurotransmitters such as serotonin (5-HT), norepinephrine (NE), γ-aminobutyric acid, and neuropeptides, resulting in a series of clinical symptoms, such as muscle tremors, stiffness, and postural disturbances , movement difficulties, etc. According to reports, there are about 1.5 million PD patients in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519A61K31/277A61P25/16
Inventor 王玉姝
Owner SUZHOU FAMO BIOLOGICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com